PTN

Company Overview — What Does PALATIN TECHNOLOGIES INC Do?

Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL3994, a natriuretic peptide receptor (NPR)-A agonist and synthetic mimetic of the endogenous neuropeptide hormone atrial natriuretic peptide for cardiovascular indications; and PL5028, an NPR-A and NPR-binder to treat cardiovascular and fibrotic diseases, including reducing cardiac hypertrophy and fibrosis. The company was incorporated in 1986 and is based in Cranbury, New Jersey. PALATIN TECHNOLOGIES INC (PTN) is classified as a micro-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Carl Spana and employs approximately 30 people, headquartered in Cranbury, New Jersey. With a market capitalization of $30M, PTN is one of the notable companies in the Healthcare sector.

PALATIN TECHNOLOGIES INC (PTN) Stock Rating — Avoid (April 2026)

As of April 2026, PALATIN TECHNOLOGIES INC receives a Avoid rating with a composite score of 21.4/100 and 1 out of 5 stars from the Blank Capital Research quantitative model.PTN ranks #4,042 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, PALATIN TECHNOLOGIES INC ranks #706 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

PTN Stock Price and 52-Week Range

PALATIN TECHNOLOGIES INC (PTN) currently trades at $18.02. The stock lost $0.33 (1.8%) in the most recent trading session. The 52-week high for PTN is $31.00, which means the stock is currently trading -41.9% from its annual peak. The 52-week low is $0.04, putting the stock 51385.7% above its annual trough. Recent trading volume was 6K shares, suggesting relatively thin trading activity.

Is PTN Overvalued or Undervalued? — Valuation Analysis

PALATIN TECHNOLOGIES INC (PTN) carries a value factor score of 18/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The trailing price-to-earnings ratio is 0.41x, compared to the Healthcare sector average of 23.63x — a discount of 98%. The price-to-book ratio stands at 2.94x, versus the sector average of 2.75x. The price-to-sales ratio is 21.37x, compared to 1.66x for the average Healthcare stock. On an enterprise value basis, PTN trades at 0.41x EV/EBITDA, versus 6.34x for the sector.

At current multiples, PALATIN TECHNOLOGIES INC trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

PALATIN TECHNOLOGIES INC Profitability — ROE, Margins, and Quality Score

PALATIN TECHNOLOGIES INC (PTN) earns a quality factor score of 10/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -194.8%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -124.6% versus the sector average of -33.1%.

On a margin basis, PALATIN TECHNOLOGIES INC reports gross margins of 100.0%, compared to 71.5% for the sector. The operating margin is -3423.9% (sector: -66.1%). Net profit margin stands at -3398.1%, versus -58.7% for the average Healthcare stock. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

PTN Debt, Balance Sheet, and Financial Health

PALATIN TECHNOLOGIES INC has a debt-to-equity ratio of 56.0%, compared to the Healthcare sector average of 32.0%. Leverage is within a manageable range for the industry, though investors should monitor debt trends over time. The current ratio is 2.76x, indicating strong short-term liquidity. Cash and equivalents stand at $1M.

PTN has a beta of 10.18, meaning it is more volatile than the broader market — a $10,000 investment in PTN would be expected to move 918.3% more than the S&P 500 on any given day. The stability factor score for PALATIN TECHNOLOGIES INC is 7/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

PALATIN TECHNOLOGIES INC Revenue and Earnings History — Quarterly Trend

In TTM 2026, PALATIN TECHNOLOGIES INC reported revenue of $2M and earnings per share (EPS) of $-2.86. Net income for the quarter was $-22M. Operating income came in at $-23M.

In Q2 2026, PALATIN TECHNOLOGIES INC reported revenue of $116,036 and earnings per share (EPS) of $-2.86. Net income for the quarter was $-7M. Operating income came in at $-7M.

In FY 2025, PALATIN TECHNOLOGIES INC reported revenue of $0. Net income for the quarter was $-17M. Operating income came in at $-17M.

In Q3 2025, PALATIN TECHNOLOGIES INC reported revenue of $0. Net income for the quarter was $-5M. Operating income came in at $-5M.

Over the past 8 quarters, PALATIN TECHNOLOGIES INC has demonstrated a growth trajectory, with revenue expanding from $0 to $2M. Investors analyzing PTN stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

PTN Dividend Yield and Income Analysis

PALATIN TECHNOLOGIES INC (PTN) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

PTN Momentum and Technical Analysis Profile

PALATIN TECHNOLOGIES INC (PTN) has a momentum factor score of 45/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 25/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 13/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.

PTN vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, PALATIN TECHNOLOGIES INC (PTN) ranks #706 out of 838 stocks based on the Blank Capital composite score. This places PTN in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing PTN against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full PTN vs S&P 500 (SPY) comparison to assess how PALATIN TECHNOLOGIES INC stacks up against the broader market across all factor dimensions.

PTN Next Earnings Date

No upcoming earnings date has been announced for PALATIN TECHNOLOGIES INC (PTN) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy PTN? — Investment Thesis Summary

The quantitative profile for PALATIN TECHNOLOGIES INC suggests caution. The quality score of 10/100 flags below-average profitability. The value score of 18/100 indicates premium valuation. High volatility (stability score 7/100) increases portfolio risk.

In summary, PALATIN TECHNOLOGIES INC (PTN) earns a Avoid rating with a composite score of 21.4/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on PTN stock.

Related Resources for PTN Investors

Explore more research and tools: PTN vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare PTN head-to-head with peers: PTN vs AZN, PTN vs SLGL, PTN vs VMD.